EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with alcohol use disorder and liver disease at a liver transplant center

J Watt, K C Morley iD, P S Haber iD, D Seth iD, A Volovets

Alcohol, Clinical and Experimental Research · 2025

DOI: 10.1111/acer.70133 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Alcohol, Clinical and Experimental Research, 2025. Verfasst von J Watt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Glycerophospholipids, Liver Transplantation, Alcohol Drinking, Alcoholism. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phosphatidylethanol (PEth), ethyl glucuronide (EtG), and ethyl sulphate (EtS) are highly sensitive and specific biomarkers of alcohol intake. This study investigated their application and relationship to traditional self‐report measures in a mixed cohort of liver disease patients to guide decision making in liver transplant populations.

Methods

We recruited 183 participants (mean age 49.2 years, 62% male), with N = 99 liver disease (88% alcohol‐associated liver disease [ALD]), N = 35 alcohol use disorder (AUD), and N = 49 healthy volunteers. Patient‐reported alcohol intake and AUDIT score served as references and were compared to traditional biomarkers, PEth and serum EtG/EtS. Receiver operating characteristic (ROC) analysis and a range of biomarker cutoffs were examined to determine optimal test characteristics. A subset of blood samples modified to a standardized hematocrit analyzed the relationship between hematocrit and PEth.

Results

Compared to traditional biomarkers, both PEth and EtG were sensitive and specific for alcohol intake. At the limit of detection (LOD), PEth was 95% sensitive at detecting any drinking. PEth cutoff of 300 μg/L was 86% sensitive and 92% specific for “heavy drinking,” and 600 μg/L was 88% sensitive and specific for “very heavy drinking.” PEth displayed superior test characteristics (sensitivity, specificity, PPV, NPV, and AUC) to all measured traditional biomarkers over two‐day and one‐month time frames. A subset of participants suspected of drinking but reporting abstinence had positive PEth tests (35%), suggestive of unreported drinking. PEth was positively correlated with hematocrit ( r 2 = 0.83, p < 0.01) and correction to a standardized median resulted in increases in PEth concentration in most cases.

Conclusions

PEth is clinically useful as an alcohol biomarker in patients with liver disease and is superior to traditional biomarkers, providing good test characteristics for “heavy” and “very heavy” drinking using stepwise cutoffs. PEth detected a subset of patients underreporting their alcohol use, with implications for the management of patients in liver transplant clinics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycerophospholipidsLiver TransplantationAlcohol DrinkingAlcoholismLiver DiseasesHumansMaleFemaleBiomarkersMiddle AgedAdultGlucuronatesSulfuric Acid Esters

Stichwörter der Autor:innen

alcohol use disorderalcohol‐associated liver diseasebiomarker studyliver transplantphosphatidylethanol

Substanzen

GlycerophospholipidsphosphatidylethanolBiomarkersethyl glucuronideGlucuronatesSulfuric Acid Estersdiethyl sulfate

Autor:innen und Institutionen

  • Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Edith Collins Centre (Translational Research in Alcohol Drugs and Toxicology), Drug Health Services, Sydney, New South Wales, Australia.
  • Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, New South Wales, Australia.
  • Anastasia Volovets MBBS, FRACP, AW Morrow Gastroenterology and Liver Centre and Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: K C Morley, P S Haber, D Seth

Zitieren

APA

Watt, J., Morley, K. C., Haber, P. S., Seth, D., & Volovets, A. (2025). Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with alcohol use disorder and liver disease at a liver transplant center. Alcohol, Clinical and Experimental Research. https://doi.org/10.1111/acer.70133

Vancouver

Watt J, Morley KC, Haber PS, Seth D, Volovets A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with alcohol use disorder and liver disease at a liver transplant center. Alcohol, Clinical and Experimental Research. 2025. doi:10.1111/acer.70133

BibTeX
@article{Watt2025,
  author = {Watt, J and Morley, K C and Haber, P S and Seth, D and Volovets, A},
  title = {Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with alcohol use disorder and liver disease at a liver transplant center},
  journal = {Alcohol, Clinical and Experimental Research},
  year = {2025},
  doi = {10.1111/acer.70133}
}
Kostenlos starten →